{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:16:44Z","timestamp":1788553004903,"version":"build-2803163510"},"reference-count":42,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Participation in clinical trials imposes additional time commitments beyond routine care; however, trial-associated time toxicity (TT) remains underinvestigated and poorly characterized. The purpose of this study was to develop a scalable, procedure-based metric to quantify total time required for trial participation using the protocol schedule of events. We applied this framework to lung cancer clinical trials to estimate trial-associated burden and explore changes in TT over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      Protocols for clinical trials associated with United States (US) Food and Drug Administration (FDA) approvals of oral lung cancer therapies were obtained from public sources. Using each protocol's schedule of events, study-mandated procedures were assigned time toxicity units (TTUs) based on standardized time estimates. TTUs for each procedure were multiplied by their frequency and summed for screening through cycle 5 to determine a trial's total time toxicity (TTT). Days with health care contact (DHC) were summed over the same period to determine total DHC (TDHC). Median (m) TTT and TDHC were compared between studies published in 2005-2014 and 2015-2024 to assess temporal trends. Two-sample Mann-Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      tests were used for nonparametric comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Thirty-two phase-specific protocols from trials published between 2005 and 2024 were included. Among studies published in 2005-2014 (n = 7), the median TTT (mTTT) was 63.8 (41.8-109.3) versus 82 (50.3-139.5) in 2015-2024 (n = 25) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .042). Corresponding median TDHC values were 14 (10-21) versus 15 (11-44), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .16).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>More contemporary studies demonstrated higher TTT, with significantly greater mTTT observed in studies published in 2015-2024 versus 2005-2014. TDHC demonstrated less sensitivity in capturing differences in time burden. These findings demonstrate the feasibility and practical applicability of the proposed TT framework for characterizing protocol-associated time burden. Prospective validation and broader implementation may help inform patients and encourage streamlined protocol development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-26-00295","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:59:16Z","timestamp":1788551956000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing Time Toxicity in Lung Cancer Clinical Trials: Development and Application of a Novel Time Burden Metric"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2590-8262","authenticated-orcid":true,"given":"Amanda","family":"Herrmann","sequence":"first","affiliation":[{"name":"UC San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-1247","authenticated-orcid":true,"given":"Sonia","family":"Jain","sequence":"additional","affiliation":[{"name":"Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-4736","authenticated-orcid":true,"given":"Lisa","family":"Madlensky","sequence":"additional","affiliation":[{"name":"Division of Genomics and Precision Medicine, Department of Medicine, UC San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-4359","authenticated-orcid":true,"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100939"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01030"},{"key":"e_1_3_8_4_2","first-page":"105","volume-title":"Overcoming Barriers to Clinical Trial Enrollment","author":"Nipp RD","year":"2019","unstructured":"Nipp RD, Hong K, Paskett ED: Overcoming Barriers to Clinical Trial Enrollment. Alexandria, VA: American Society of Clinical Oncology Educational Book 39:105-114, 2019"},{"key":"e_1_3_8_5_2","first-page":"185","volume-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","author":"Unger JM","year":"2016","unstructured":"Unger JM, Cook E, Tai E, et al: The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Alexandria, VA: American Society of Clinical Oncology Educational Book 35:185-198, 2016"},{"key":"e_1_3_8_6_2","first-page":"237437352412376","article-title":"\u201cThere was no opportunity to express good or bad\u201d: Perspectives from patient focus groups on patient experience in clinical trials","volume":"11","author":"Boyd P","year":"2024","unstructured":"Boyd P, Sternke EA, Tite DJ, et al: \u201cThere was no opportunity to express good or bad\u201d: Perspectives from patient focus groups on patient experience in clinical trials. J Patient Exp 11:23743735241237684, 2024","journal-title":"J Patient Exp"},{"key":"e_1_3_8_7_2","volume-title":"Streamlining Clinical Trials Working Group: Working Group Report","author":"Mandrekar S","year":"2024","unstructured":"Mandrekar S, Meropol N. Streamlining Clinical Trials Working Group: Working Group Report. Bethesda, MD: National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTCAE), 2024"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae239"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2023-0031"},{"key":"e_1_3_8_10_2","first-page":"LBA8671","article-title":"PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer","volume":"43","author":"Redman MW","year":"2025","unstructured":"Redman MW, Reckamp KL, Khalil M, et al: PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. J Clin Oncol 43:LBA8671, 2025","journal-title":"J Clin Oncol"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08487-2"},{"key":"e_1_3_8_12_2","first-page":"1756","article-title":"Data driven approach to burden of treatment measurement: A study of patients with breast cancer","author":"Cheng AC","year":"2017","unstructured":"Cheng AC, Levy MA: Data driven approach to burden of treatment measurement: A study of patients with breast cancer. AMIA Annu Symp Proc, 1756-1763, 2017","journal-title":"AMIA Annu Symp Proc"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00328"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235677"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102046"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4278"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00811"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3461"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00737"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00334"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag096"},{"key":"e_1_3_8_23_2","unstructured":"National Cancer Institute: Drugs Approved for Lung Cancer. National Cancer Institute 2024. http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/lung"},{"key":"e_1_3_8_24_2","unstructured":"US Food and Drug Administration: Drug Approvals and Databases. US Food and Drug Administration 2024. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases"},{"key":"e_1_3_8_25_2","unstructured":"Beck Depression Inventory. In: Salkind NJ ed. Encyclopedia of Measurement and Statistics. Vol.3. Thousand Oaks CA: SAGE Publications Inc. 83-83 2007"},{"key":"e_1_3_8_26_2","unstructured":"Columbia University Department of Psychiatry: Columbia-Suicide Severity Rating Scale (C-SSRS). https:\/\/www.columbiapsychiatry.org\/research-labs\/columbia-suicide-severity-rating-scale-c-ssrs"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.2196\/mhealth.9486"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.08.014"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.2217\/lmt-2016-0010"},{"key":"e_1_3_8_30_2","volume-title":"National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Measurement System: An Overview","author":"Mitchell SA","unstructured":"Mitchell SA. National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Measurement System: An Overview. Bethesda, MD: National Cancer Institute: Division of Cancer Control & Population Sciences, 2020 https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/overview_presentation.pdf"},{"key":"e_1_3_8_31_2","unstructured":"IQVIA. Cancer Therapy Satisfaction Questionnaire (CTSQ). IQVIA Quality Metric Inc; https:\/\/coas.iqvia.com\/COAs\/a037s000002rG8jQAE\/cancer-therapy-satisfaction-questionnaire"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-03007-9"},{"key":"e_1_3_8_33_2","unstructured":"IQVIA. Visual Symptom Assessment Questionnaire. IQVIA Quality Metric Inc. https:\/\/coas.iqvia.com\/COAs\/a037S000002rG8kQAE\/visual-symptom-assessment-questionnaire"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00073.x"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/24.2.120"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5651"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.012"},{"key":"e_1_3_8_38_2","unstructured":"FACIT: Functional Assessment of Chronic Illness Therapy - Item GP5. https:\/\/www.facit.org\/measures\/facit-item-gp5"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.08.046"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00315-z"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0379"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0699-1"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31816b9027"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:59:19Z","timestamp":1788551959000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":42,"alternative-id":["10.1200\/OP-26-00295"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00295","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"2026-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00295"}}